Plain-English translation of NCT07183280 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Researchers are building a large database by collecting medical information from patients across multiple hospitals who have been diagnosed with solid pseudopapillary neoplasm (SPN) of the pancreas โ a rare, slow-growing pancreatic tumor that mainly affects younger people. By gathering real-world data from everyday clinical care, the study aims to better understand how this tumor develops, who is most at risk, and what treatments work best. This information will help doctors make better decisions for future patients.
Although SPN is a rare pancreatic tumor with generally good outcomes, about 1 in 10 patients develop metastasis or recurrence, and doctors still have much to learn about which patients are at highest risk and how to treat them best. By collecting information from many patients across different hospitals, researchers hope to discover patterns that will improve diagnosis and care for people with this condition.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
Your participation involves allowing researchers to collect and analyze your medical records and clinical information as part of ongoing care โ there is no separate experimental treatment or medication involved. The study will track your health information over time as you receive standard care from your doctors. You will need to be able to attend follow-up appointments and cooperate with the research team as they gather data from your medical visits.
AI-generated summary from trial data ยท Jul 21, 2026 ยท Not medical advice
China
Sponsor
Fudan University
Enrollment target
~2,000 participants
Started
September 2025
Primary completion
December 2040
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Huanyu Xia, MD
Shanghai Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.